<Back to Therapeutic Areas

Immunology

Meet Us

RWCS | Feb 12-15, 2020 | Maui, HI

ACR SOTA | May 16-17, 2020 | Virtual

CCR East | Sep 5-8, 2020 | Destin, FL

CCR West | Oct 1-4, 2020 | San Diego, CA

ACR Convergence | Nov 6-11, 2020 | Washington, D.C

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Phase II Phase III Phase IV

SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

NCT01729455

Belimumab Pregnancy Registry

NCT01532310

BLISS-LN: Belimumab in Active Lupus Nephritis

NCT01639339

BLISS-BELIEVE: Belimumab Subcutaneous in Combination with Rituximab in Adult SLE

NCT03312907
RHEUMATOID ARTHRITIS (RA) Phase II Phase III Phase IV

ContRAst-1: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

NCT03980483

ContRAst-2: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active RA who have Inadequate Response to Conventional Synthetic DMARDs

NCT03970837

ContRAst-3: Otilimab vs Placebo and Sarilumab in Moderately to Severely Active RA with Inadequate Response to Biologic DMARDs and/or JAKI

NCT04134728

Mechanistic Study of Otilimab Plus Methotrexate in Active Rheumatoid Arthritis Despite Treatment With DMARDs

NCT02799472
(Phase IIa)

Otilimab Plus Methotrexate in Active Moderate-Severe Rheumatoid Arthritis

NCT02504671
(Phase IIb)
INFLAMMATORY BOWEL DISEASE Phase II Phase III Phase IV

Study of anti-LAG3 in Ulcerative Colitis

NCT03893565
EOSINOPHILIC GRANULOMATOSIS
WITH POLYANGIITIS (EGPA)
Phase II Phase III Phase IV

VCRC-VPPRN EGPA Registry (Observational Study)*

NCT00315380 (Observational)
SJÖGREN’S SYNDROME Phase II Phase III Phase IV

Belimumab Subcutaneous and Intravenous Rituximab Co-Administered in Primary Sjögren’s Syndrome

NCT02631538
SYSTEMIC SCLEROSIS Phase II Phase III Phase IV

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

NCT03041025
Definitions:
  • BLyS = B Lymphocyte Stimulator;
  • DMARDs = Disease-Modifying Anti-Rheumatic Drugs;
  • GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor;
  • JAKI = Janus Kinase Inhibitor;
  • LAG-3 = Lymphocyte Activation Gene-3 Protein;
  • OSM = Oncostatin M;
  • VCRC = Vasculitis Clinical Research Consortium;
  • VPPRN = Vasculitis Patient-Powered Research Network
  • *Supported in part by GSK

Unlocking the secrets of the immune system

On-Demand Webinars

Presented By: Dr. Michelle Petri MD, MPH

Unrecognized Impact of Organ Damage in SLE (Brief)

Unrecognized Impact of Organ Damage in SLE (Full length)

International Congress on Systemic Lupus Erythematosus (Lupus 2019)

April 5-8, 2019 | San Francisco, California

European League Against Rheumatism (EULAR)

June 12-15, 2019 | Madrid, Spain

  Contact Us